Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-barecetamab-DFO
- Development stage
- Unknown
- Lead developer
- Actinium Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
89Zr-ATNM-400 (also known as 89Zr-barecetamab-DFO) is an investigational, zirconium-89-labeled antibody radioconjugate developed by Actinium Pharmaceuticals. It consists of the fully human monoclonal antibody barecetamab (formerly ISU104), which targets human epidermal growth factor receptor 3 (HER3/ErbB3), conjugated to the chelator deferoxamine (DFO) and radiolabeled with the positron-emitting isotope zirconium-89 (89Zr). Developed as a diagnostic companion imaging agent (theranostic partner) to the therapeutic Actinium-225-labeled radioconjugate ATNM-400 (225Ac-barecetamab-DOTA), 89Zr-ATNM-400 is utilized in positron emission tomography (PET) imaging to visualize tumor uptake, assess biodistribution, and perform dosimetry. This imaging helps select patients and optimize dosing for the therapeutic counterpart in solid tumors, including metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer, and ovarian cancer.
- Other names
- 89Zr-barecetamab89Zr-barecetamab-DFO[89Zr]-barecetamab-DFOzirconium-89-labeled barecetamabzirconium89-labeled barecetamabzirconium 89-labeled barecetamab
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on 89Zr-barecetamab-DFO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-barecetamab-DFO.